Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab...
Drug: Cisplatin Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles ... Drug: Cisplatin Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles ... Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab ... Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab ...https://clinicaltrials.gov/ct2/show/record/NCT00620971
Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for...
This study is investigating the efficacy and safety of cisplatin combined with gimeracil/oteracil/tegafur [S-1] compared with ... Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for ... Phase III study of cisplatin plus S-1 (CS) compared with docetaxel and cisplatin plus S-1 (DCS) as first-line therapy for ...http://adisinsight.springer.com/trials/700215792?error=cookies_not_supported&code=c4193460-43d4-4f26-aafe-7878c5bd2382
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors - Full Text View - ClinicalTrials.gov
Regimen 1 (BEP) Cisplatin (20mg/m2/day) IV on days 1 to 5 Etoposide (100 mg/m2/day) IV on days 1 to 5 Bleomycin 30 U/IV on days ... Regimen 3 (VIP) Cisplatin (20mg/m2/day) IV on days 1 to 5 Ifosfamide (1200 mg/m2/day) IV on days 1 to 5 (with mesna ... Regimen 4 (VeIP) Cisplatin (20mg/m2/day) IV on days 1 to 5 Ifosfamide (1200 mg/m2/day) IV on days 1 to 5 (with mesna ... Regimen 2 (EP) Cisplatin (20mg/m2/day) IV on days 1 to 5 Etoposide (100 mg/m2/day) IV on days 1 to 5 ...https://clinicaltrials.gov/ct2/show/NCT00572572
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer - Tabular...
Drug: Vinorelbine followed by Cisplatin Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/ ... The proposed study is a multi-center open label phase II study of the chemotherapy doublets cisplatin/vinorelbine and cisplatin ... This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based ... Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer (TOP0703). ...https://clinicaltrials.gov/ct2/show/record/NCT00545948
Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression ...
Chk1 and Chk2 phosphorylation by cisplatin treatment. The exact mechanism of how initial cisplatin lesions are recognized and ... Overexpression of ERCC1-XPF resulted in repair of cisplatin induced ICLs and decreased cisplatin sensitivity suggesting that ... treated with cisplatin for 1 h and investigated for gH2AX formation as a marker for damage related to cisplatin ICLs 24 and 48 ... Similar data were obtained for cisplatin in ERCC1 mutated UV96 hamster cells . In renal cells cisplatin lead to sustained ...https://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-9-248
Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer
Cisplatin-based chemotherapy is the standard therapy used for the treatment of several types of cancer. However, its efficacy ... Differences in gene expression profiles and carcinogenesis pathways involved in cisplatin resistance of four types of cancer. * ... To date, little is known about the RNA expression changes in cisplatin-resistant cancers. Identification of the RNAs related to ... A signal transduction network was established to identify the core genes in regulating cancer cell cisplatin resistance. A ...https://spandidos-publications.com/or/30/2/596
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix - Full Text...
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix. This study has ... concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin ... followed by adjuvant gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy without ... and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix ...https://clinicaltrials.gov/ct2/show/NCT00191100?term=
Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro |...
The median survival periods for the cisplatin, vandetanib, vandetanib plus cisplatin, radiation, cisplatin plus radiation, ... The median survival periods for the cisplatin, vandetanib, vandetanib plus cisplatin, radiation, cisplatin plus radiation, ... cisplatin (3) vandetanib (4), vandetanib plus cisplatin (5), radiation (6), cisplatin plus radiation (7), vandetanib plus ... Cisplatin was purchased from Sigma-Aldrich as a stock solution of 1 mg/mL. For animal studies, cisplatin was diluted in 0.9% ...http://clincancerres.aacrjournals.org/content/17/7/1815
Transscleral permeability and intraocular concentrations of cisplatin from a collagen matrix. - Semantic Scholar
Cisplatin had a peak in vitro scleral permeability constant of 8.3+/-1.2 x 10(-6) and 20.1+/-1.8 x 10(-6) cm/s, delivered in ... Cisplatin in either a collagen matrix vehicle or a control balanced salt solution (BSS) vehicle was applied to human sclera ... The amount of cisplatin that diffused across the sclera was measured in hourly samples for 24 h using atomic absorption ... Subconjunctival injection of cisplatin in the collagen matrix vehicle achieved 3.3+/-0.1 microg/ml in the vitreous humor at 1.5 ...https://www.semanticscholar.org/paper/Transscleral-permeability-and-intraocular-concentr-Gilbert-Simpson/9b4156e1b5058dd32d36142212bfe98197f8d3e9
Long-Term In vivo Effects of Cisplatin on γ-H2AX Foci Signaling in Peripheral Lymphocytes of Tumor Patients After Irradiation |...
... cisplatin mono, cisplatin/navelbine, cisplatin/etoposide), and (e) time of blood sampling from cisplatin exposure. A repeated ... b) Cisplatin resistance in tumors can be evaluated by IRIFF. (c) Cisplatin-dependent IRIFF in lymphocytes and tumor cells after ... Although the cisplatin effect on γ-H2AX foci remained relatively constant during the first 3 to 4 days after cisplatin exposure ... Although the effect of cisplatin dose (P = 0.66; F-test) and the number of the cisplatin application (P = 0.49; F-test) were ...http://clincancerres.aacrjournals.org/content/15/8/2927
A randomized phase II study of gemcitabine/cisplatin with or without cetuximab to evaluate the efficacy in patients with...
A randomized phase II study of gemcitabine/cisplatin with or without cetuximab to evaluate the efficacy in patients with ... A randomized phase II study of gemcitabine/cisplatin with or without cetuximab to evaluate the efficacy in patients with ...http://adisinsight.springer.com/trials/700027582?error=cookies_not_supported&code=f5572d54-0f79-4c26-b714-cf1472db48ff
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer - Full Text...
Drug: Vinorelbine followed by Cisplatin Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/ ... Drug: Vinorelbine followed by Cisplatin Drug: Pemetrexed followed by Cisplatin Phase 2 ... This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based ... Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer (TOP0703). ...https://clinicaltrials.gov/show/NCT00545948
Cisplatin-resistant human ovarian cancer SK-OV cells, which are retaining 25-fold higher levels of GSH than murine fibroblasts ... The treatment of alkylating cytotoxic drug cisplatin is often limited by high incidence rate of resistance. In the present ... Nrf2-deficient murine embryonic fibroblasts showed increased cell death, cytotoxicity, and apoptosis in response to cisplatin ... with Nrf2 siRNA into SK-OV cells resulted in severe degree of GSH depletion and exacerbated cytotoxicity following cisplatin ...http://cancerres.aacrjournals.org/content/68/9_Supplement/705
Cisplatin - National Cancer Institute
This page contains brief information about cisplatin and a collection of links to more information about the use of this drug, ... Cisplatin is approved to be used alone or with other drugs to treat:. *Bladder cancer that cannot be treated with surgery or ... More About Cisplatin. Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug. ... MedlinePlus Information on Cisplatin - A lay language summary of important information about this drug that may include the ...https://www.cancer.gov/about-cancer/treatment/drugs/cisplatin
Cisplatin - Wikipedia
Cisplatin: The Invention of an Anticancer Drug by Andri Smith. *Anti-cancer Agents: A treatment of Cisplatin and their ... Cisplatin resistanceEdit. Cisplatin combination chemotherapy is the cornerstone of treatment of many cancers. Initial platinum ... "Cisplatin". International Drug Price Indicator Guide. Retrieved 8 December 2016.. *^ British national formulary: BNF 69 (69 ed ... Cisplatin". Annals of Internal Medicine. 100 (5): 704-13. doi:10.7326/0003-4819-100-5-704. PMID 6370067.. ...https://en.m.wikipedia.org/wiki/Cisplatin
P&U Cisplatin - Drugs.com
A list of US medications equivalent to P&U Cisplatin is available on the Drugs.com website. ... P&U Cisplatin is a medicine available in a number of countries worldwide. ... Ingredient matches for P&U Cisplatin. Cisplatin. Cisplatin is reported as an ingredient of P&U Cisplatin in the following ... P&U Cisplatin. P&U Cisplatin may be available in the countries listed below. ...https://www.drugs.com/international/p-u-cisplatin.html
Cisplatin - Drug Information - Chemocare
Cisplatin (Platinol, CDDP) chemotherapy side effects, how it's given, how it works, precautions and self care tips for treatent ... If cisplatin escapes from the vein it can cause tissue damage. The nurse or doctor who gives cisplatin must be carefully ... Cisplatin side effects will improve after therapy is complete.. *Cisplatin side effects may be quite manageable. There are many ... How Cisplatin Is Given:. *Cisplatin is administered through a vein (intravenously or IV) as an infusion. ...http://chemocare.com/chemotherapy/drug-info/cisplatin.aspx
The Cisplatin-Induced Cellular Injury Response | SpringerLink
Treatment of cells with clinically relevant exposures to cisplatin (DDP) activates an injury response that eventually induces ... Cisplatin: A preclinical overview. In: Prestayko AW, Crooke ST, Carter SK, eds. Cisplatin: Current Status and New Developments ... Modulation of cisplatin sensitivity and growth rate of an ovarian carcinoma cell line by bombesin and tumor necrosis factor ... Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp ...https://link.springer.com/chapter/10.1007/978-1-4899-0218-4_25
Cisplatin - Information and support - Macmillan Cancer Support
What is cisplatin?. Cisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, and non-small ... How cisplatin is given. You usually have cisplatin in the chemotherapy day unit or during a stay in hospital. A chemotherapy ... Each cycle of cisplatin usually takes 21 days (three weeks). You usually have the cisplatin on the first day of the cycle. But ... Possible side effects of cisplatin. We explain the most common side effects of cisplatin here. But we don't include all the ...https://www.macmillan.org.uk/information-and-support/lung-cancer/small-cell-lung-cancer/treating/chemotherapy/drugs-and-combination-regimens/individual-drugs/cisplatin.html
Abiplatin (Cisplatin) Teva
Injectable; Injection; Cisplatin 0.5 mg / ml*Injectable; Injection; Cisplatin 1 mg / ml. ...http://drugs-about.com/drugs-a/abiplatin.html
Chemotherapeutic Synergy: Cisplatin | GreenMedInfo | Keyword
The combined use of 1,25(OH)2D3 and cisplatin may be used as a strategy to overcome resistance to cisplatin and dose ... Magnesium improves cisplatin-mediated tumor killing while protecting against cisplatin-induced nephrotoxicity.Jul 31, 2017. ... Curcumin potentiates Cisplatin-induced proliferation inhibitory effect and apoptosis in A549 and Cisplatin resistant lung ... Additional Keywords : Chemotherapeutic Synergy: Cisplatin, Chemotherapy-Induced Toxicity: Cisplatin, Inflammation, Lipid ...http://www.greenmedinfo.com/keyword/chemotherapeutic-synergy-cisplatin
Cisplatin (IARC Summary & Evaluation, Volume 26, 1981)
CISPLATIN. VOL.: 26 (1981) (p. 151) 5. Summary of Data Reported and Evaluation. 5.1 Experimental data. Cisplatin was tested by ... See Also: Toxicological Abbreviations Cisplatin (PIM 132) Cisplatin (UKPID) ... Cisplatin has been used since the 1970s primarily in the treatment of testicular and ovarian cancer, often in combination with ... Cisplatin is a mutagen in bacterial and cultured mammalian cells. It also induces chromosomal aberrations in various cells in ...http://www.inchem.org/documents/iarc/vol26/cisplatin.html
Cisplatin & fluorouracil - Information and support - Macmillan Cancer Support
If you or someone close to you has been diagnosed with cancer, you're not alone. Find out what to expect, get information, practical advice and support, hear from experts and read about other people's experiences.https://www.macmillan.org.uk/information-and-support/lung-cancer/small-cell-lung-cancer/treating/chemotherapy/drugs-and-combination-regimens/combination-chemotherapy/docetaxel-and-cisplatin.html
Cisplatin News | SciTechDaily
... chemists have developed a new way to kill cancer cells that have shown resistance to cisplatin. Cisplatin… ... By targeting mitochondria with the anticancer drug cisplatin, ...https://scitechdaily.com/tag/cisplatin/
cisplatin - UNM Comprehensive Cancer Center
The DNA damage caused by cisplatin results in cellular death.. How is cisplatin typically given (administered)? Cisplatin can ... What is the mechanism of action? Cisplatin belongs to a group of drugs called alkylating agents. Cisplatin produces its anti- ... In addition, cisplatin may cause damage to tissues it comes into contact with if it should leak out of the vein through which ... A neurologic exam, including testing reflexes, will be performed as cisplatin may result in loss of sensation in hands, feet or ...http://cancer.unm.edu/2009/04/28/cisplatin-3/